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We describe two cases of hypertension and hypokalemia due to mineralocorticoid excess caused by
posaconazole treatment of coccidioidomycosis and rhinocerebral mucormycosis infections, re-
spectively. Clinical laboratory evaluations, including a comprehensive analysis of blood and urine
steroid profiles, revealed low renin and aldosterone and indicated as the underlying mechanism
primarily a block of 11b-hydroxylase activity in patient 1, whereas patient 2 displayed weaker 11b-
hydroxylase but more pronounced 11b-hydroxysteroid dehydrogenase 2 inhibition. The results show
that both previously suggested mechanisms must be considered and emphasize significant in-
terindividual differences in the contribution of each enzyme to the observed mineralocorticoid excess
phenotype. The mineralocorticoid symptoms of patient 1 resolved after replacement of posaconazole
therapy by isavoconazole, and posaconazole dosage de-escalation ameliorated the effects in patient 2.
By providing a thorough analysis of the patients’ blood and urine steroid metabolites, this report adds
further evidence for two individually pronounced mechanisms of posaconazole-induced hypertension
and hypokalemia. The elucidation of the factors responsible for the individual phenotype warrants
further research.
Copyright © 2019 Endocrine Society
This article has been published under the terms of the Creative Commons Attribution Non-
Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-
nd/4.0/).
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1. Case Reports
Recent case reports describing posaconazole-induced mineralocorticoid excess suggested
two distinct mechanisms promoting the observed hypertension and hypokalemia: in-
hibition of the adrenal enzyme 11b-hydroxylase [1, 2] or the peripheral cortisol metabo-
lizing 11b-hydroxysteroid dehydrogenase 2 (11b-HSD2) [2–5]. Themajority of these studies
did not evaluate the patient’s steroid profile in blood and urine, allowing only a limited
understanding of the relative contribution of the two enzymes leading to the drug-induced
hypertension and hypokalemia. Therefore, we conducted a detailed analysis of blood and
urine steroid metabolites for the two presented cases to address this issue.
Abbreviations: 11b-HSD2, 11b-hydroxysteroid dehydrogenase 2; 11-DHC, 11-dehydrocorticosterone; 11-DOC, 11-deoxy-
corticosterone; UHPLC-MS/MS, ultra-high-performance liquid chromatography–tandem mass spectrometry.
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2. Patient 1
A 54-year-old man with no past medical history presented with fever, chills, cough, and
weight loss. His initial examination, vital signs (blood pressure 127/90 mm Hg), and
chemistry and laboratory values (chem 10 test, liver function profile) were normal with the
exception of positive serologic testing for coccidioidomycosis. Therefore, he was placed on
fluconazole 600 mg daily. However, over the next 6 weeks he developed nausea and cheilitis
and xerosis that were attributed to fluconazole therapy, and he was transitioned to pos-
aconazole 300 mg daily. His systemic and respiratory symptoms improved; however, he
developed new-onset hypertension (163/94 mm Hg) and hypokalemia (3.1 mmol/L) 8 weeks
after starting posaconazole therapy. Besides posaconazole, he received only pantoprazole.
Because of suspected posaconazole-induced mineralocorticoid excess, an initial clinical
laboratory evaluation was obtained, revealing very low renin (0.2 ng/mL/h) and undetectable
aldosterone values (,3.0 ng/dL) but elevated concentrations of estradiol (49 pg/mL) and
11-deoxycortisol (320 ng/dL) and a posaconazole serum blood concentration of 3.1 mg/mL.
Serum electrolyte concentrations were normal with the exception of continued hypokalemia
(3.0 mmol/L). Treatment was continued and serum was obtained again 4 weeks later, with
posaconazole levels of 2.7 mg/mL at that time. To gain closer insight into the mechanism
of the posaconazole-induced mineralocorticoid excess, a comprehensive serum (Table 1) and
urinary (Table 2) steroid analysis was performed with ultra-high-performance liquid
chromatography–tandem mass spectrometry (UHPLC-MS/MS). The results confirmed se-
rum aldosterone concentrations below the limit of detection, low corticosterone (42 ng/dL) and
androstenedione (45 ng/dL) concentrations, and moderately elevated concentrations of 11-
deoxycortisol (216 ng/dL) (Table 1), suggesting inhibition of 11b-hydroxylase. Normal serum
levels were detected for cortisol (7.4 mg/dL), cortisone (1.65 mg/dL), 11-dehydrocorticosterone
(11-DHC) (36 ng/dL), 11-deoxycorticosterone (11-DOC) (8.3 ng/dL), 17-hydroxyprogesterone
[17-OH progesterone (102 ng/dL)], testosterone (242 ng/dL), and androstenedione (46 ng/dL).
Analysis of 24-hour urine revealed undetectable levels of aldosterone and very low
tetrahydroaldosterone (4.95 mg/24 h) but normal concentrations of cortisol (111 mg/24 h),
cortisone (113 mg/24 h), and their tetrahydro-metabolites (Table 2). Importantly, urinary 11-
deoxycortisol (1.99 mg/24 h) and 11-DOC (2.96 mg/24 h) were markedly elevated, supporting
an inhibition of 11b-hydroxylase. 17-OH progesterone (2.11 mg/24 h) was slightly elevated,
and androgen metabolites were normal or low. Creatinine from the 24-hour urine collection
was 61 mg/dL, and total creatinine 1552 mg.
Table 1. Detailed Analysis of Steroids in Blood From Posaconazole-Treated Patients
Steroid Patient 1 Patient 2 Reference Range
Aldosterone, ng/dL nd nd 2.0–18
Cortisol (F), mg/dL 7.4 5.2 5.0–25
Cortisone (E), mg/dL 1.65 0.19a 1.0–3.5
F/E 4.5 27b 2–8
Corticosterone (B), ng/dL 42a 54a 62–1600
11-DHC (A), ng/dL 36 6.5 nr
B/A 1.16 8.3 nr
11-deoxycortisol, ng/dL 216b 186b ,158
11-DOC, ng/dL 8.3 3.2 2.0–19
Testosterone, ng/dL 242 32a 200–1070
Androstenedione, ng/dL 46 3.8a 30–250
17-OH progesterone, ng/dL 101 36 5–250
Steroids were quantified in a serum sample and a whole blood sample from patient 1 and patient 2, respectively.
Samples were collected at 8 AM and analyzed by UHPLC-MS/MS [6]. Reference ranges are for men, age 20–50,
samples taken between 8 and 10 AM, supine position [7, 8].
Abbreviations: nd, below lower limit of detection; nr, not reported.
aBelow normal range.
bAbove normal range.
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Posaconazole therapy was discontinued, and isavuconazole (186 mg daily) was initiated.
On follow-up 6 weeks later, the patient’s hypertension and hypokalemia had resolved (134/
92 mm Hg and 4.3 mmol/L, respectively).
3. Patient 2
A 73-year-old man with a past medical history of multiple myeloma presented 3 months after
initiation of dexamethasone and chemotherapy. He complained of left eye swelling and pain of
1 week’s duration and was found on MRI to have maxillary sinus thickening with erosion and
Table 2. Comprehensive Analysis of Steroids in Urine From Posaconazole-Treated Patients














Cortisol (F) 111 71 57 60 35–168
Cortisone (E) 113 73 29.5 31a 92–366
F/E 0.98b 1.95b 0.28–0.85
a-THF 626a 403 612 644a 796–2456
b-THF 1647 1061 1214 1277 942–2800
a-THE 69 44 22.1 23a 62–752
b-THE 2569 1655 516 543a 1365–5788
sumTHF/sumTHE 0.86 b 3.39 0.66–1.44
Corticosterone (B) 6.35b 4.1 2.21 2.33 0.2–4.8
11-DHC (A) 12.4 8.0 3.11 3.27a 6–40
B/A 0.51 0.71 nr
b-THB 348b 224 392 413 40–326
a-THB 370 238 119 126 86–588
b-THA 220b 142 21.8 23 3–65
a-THA 58b 37 24.1 25 2–29
sumTHB/sumTHA 2.58 11.1
11-Deoxycortisol 1.99b 1.28 1.24 1.31b ,0.5
11-Deoxy-corticosterone 2.96b 1.91 1.37 1.44b 0.1–0.5
Aldosterone nda nd nd nda 2.3–21
TH-aldo 4.95a 3.19 nd 6–79
18-OH-F 23a 15 2.74 2.88a 51–515
18-OH-corticosterone 9.87b 6.4 1.30 1.37 1.5–6.5
a-Cortolone 1489 959 263 276a 333–1667
b-Cortolone 976 629 185 194 249–1049
b-Cortol 579b 373 256 270 70–336
Testosterone 6.87 4.4 0.56 0.59a 3–47
Androstenedione 19.9a 12.8 2.62 2.76a 50–220
Etiocholanolone 1406 906 192 202 430–3300
Androsterone 1315 847 271 285 320–5400
17-OH-progesterone 2.11b 1.4 1.40 1.47 0.2–1.5
11-Keto-etiocholanolone 315 203 nd nda 79–1026
11b-OH-etiocholanolone 864 557 39 41a 18–1034
11b-OH-androsterone 113a 73 26 27a 500–1733
Progesterone 2.62a 1.69 1.47 1.55 nr
Dehydroepiandrosterone 9.46a 6.1 1.54 1.62a 21–2710
Creatinine 0.61 mg/mL 0.95 mg/mL 0.63–2.50 g/24 h
Steroids were quantified in a 24-h urine sample and a spot urine sample from patient 1 and patient 2, respectively, by
UHPLC-MS/MS. Total urine volume: 2550 mL. Reference ranges are for men, age 20–50 [8–10].
Abbreviations: 11-DHC, 11-dehydrocorticosterone; CRT, creatinine; E, cortisone; F, cortisol; nd, below lower limit of
detection; nr, not reported; OH, hydroxy; TH-aldo, tetrahydroaldosterone; THA, tetrahydro-11-dehydrocorticosterone;
THB, tetrahydrocorticosterone; THE, tetrahydrocortisone; THF, tetrahydrocortisol.
aBelow normal range.
bAbove normal range.
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inflammation of the surrounding structures, including the orbit. He immediately underwent
surgical evaluation and received a diagnosis of rhinocerebral mucormycosis (Rhizopus spp
identified on cultures and histopathology of the resected tissue). He underwent left orbital ex-
enteration and maxillectomy and was treated with liposomal amphotericin B and micafungin for
21 days.Hewas thereafter transitioned to oral posaconazole 300mg daily and discharged after 72
hours of observation and repeated surgical intervention showing no further evidence of infection.
Upon outpatient follow-up,;9weeks later, hewas noted to have new onset of hypertension
(blood pressure 154/69 mm Hg) and hypokalemia (3.3 mmol/L). All other vital signs were
within normal limits. Besides posaconazole, this patient received filgrastim, sitagliptin,
pantoprazole, and oxycodone. Physical examination found postoperative changes, left facial
numbness, and no signs of ongoing infection. Laboratory evaluation revealed low renin
(0.36 ng/mL/h), undetectable aldosterone (,2 ng/dL), and elevated 11-deoxycortisol (406 ng/dL)
concentrations and a serum osmolality of 292 mOsm/kg, indicating mineralocorticoid excess
due to posaconazole-dependent inhibition of 11b-hydroxylase. Furthermore, serum pos-
aconazole levels were high (5.0 mg/mL), and estradiol concentrations were below the limit of
detection (,15 pg/mL). Urine analyses at this time revealed spot osmolality of 292 mOsm/kg
and potassium of 23.9 mmol/L, confirming a transtubular potassium gradient of 7.24.
The patient’s posaconazole dosage was then reduced to 200mg/d. However, after 4weeks of
this treatment, renin and aldosterone levels were found to be further dramatically decreased
(,0.1 ng/mL/h and ,2 ng/dL, respectively), and posaconazole concentrations were still el-
evated (3.3 mg/mL) but lower compared with the last visit, and estradiol levels stayed
comparably low (,15 pg/mL). Again, further comprehensive blood steroid analyses were
performed and revealed normal concentrations of cortisol (5.2mg/dL) and 11-DOC (3.2 ng/dL),
low levels of corticosterone (54 ng/dL), and clearly decreased levels of cortisone (0.19 mg/dL)
and 11-DHC (6.5 ng/dL) (Table 1). 11-Deoxycortisol levels (186 ng/dL) were confirmed to be
slightly elevated. However, cortisol to cortisone (27) and corticosterone to 11-DHC ratios (8.4)
were markedly increased, indicating potent inhibition of 11b-HSD2. Testosterone and
androstenedione were very low, whereas 17-OH progesterone was normal.
Analysis of spot urine revealed elevated ratios of cortisol to cortisone (1.95) and their
tetrahydro-metabolites (3.39), supporting 11b-HSD2 inhibition (Table 2). Aldosterone and
tetrahydroaldosterone were not detectable, whereas a qualitative analysis after normali-
zation to creatinine suggested elevated levels of 11-deoxycortisol and 11-DOC, supporting
partial inhibition of 11b-hydroxylase. Spot urine creatinine was 95 mg/dL.
Subsequently, his daily posaconazole dosage was lowered to 100 mg, and 3 weeks later his
serum posaconazole level had further decreased to 1.68 mg/mL, his blood pressure had
normalized to 130/76 mm Hg, and his potassium normalized at 4.4 mmol/L. The patient
declined further laboratory evaluation due to the expense.
4. Discussion
The occurrence of hypertension and hypokalemia as adverse effects of posaconazole treat-
ment has been reported in market authorization studies [6]. Nevertheless, only recently have
several case studies addressed themechanism underlying the symptoms of mineralocorticoid
excess in more detail, with some debate about the predominantly affected enzyme [1, 2, 4, 5,
12–14]. Whereas some reports proposed 11b-HSD2 to be the cause of apparent mineralo-
corticoid excess [4, 5], others suggested 11b-hydroxylase to be responsible for the observed
phenotype [1].
The detailed analyses of blood and urine steroids in the two presented cases allowed us to
unravel the relative contribution of the two enzymes to the posaconazole-induced low-renin,
low-aldosterone hypertension and hypokalemia. The elevated 11-deoxycortisol and 11-DOC
concentrations along with normal or only slightly elevated ratios of cortisol to cortisone and
their tetrahydro-metabolites indicate inhibition of CYP11B1 (and CYP11B2) as the pre-
dominant cause in patient 1, with weak or negligible inhibition of 11b-HSD2. In contrast, the
markedly elevated ratios of active to inactive glucocorticoids, in both blood and urine, indicate
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pronounced inhibition of 11b-HSD2 in patient 2. Additionally, the moderately increased 11-
deoxycortisol revealed that CYP11B1 (and CYP11B2) was at least partially inhibited.
Patients with mineralocorticoid excess phenotype were found to generally exhibit high
serum posaconazole concentrations (.2.5 mg/mL). The factors responsible for the increased
serum levels and for the differential inhibition of CYP11B1/2 and 11b-HSD2 are not fully
understood. The interindividual differences for the enzymatic inhibitionmay be explained by
different distribution volumes limiting the concentrations of posaconazole reached in the
adrenals, necessary to inhibit 11b-hydroxylase, compared with those in the kidney or colon,
important for 11b-HSD2 inhibition.
Posaconazole ismetabolizedmainly by glucuronidation viaUGT1A4 and a potent inhibitor
of CYP3A4 and a substrate/inhibitor of the P-glycoprotein efflux transporter [15–17]. Thus,
comedication must be carefully monitored. Regarding the two presented cases, comedication
was unlikely to be a contributing factor to the onset of hypertension. Both patients received
the proton pump inhibitor pantoprazole, which increases gastric pH, thereby potentially
reducing the adsorption of posaconazole upon oral intake. No interactions with posaconazole
are known for filgrastim and sitagliptin. A reduced metabolism of oxycodone by CYP3A4
might have been occurred, however, promoting opioid-dependent adverse effects rather than
the mineralocorticoid excess. Furthermore, the bioavailability of posaconazole may be in-
creased by reduced binding to serum albumin (.98% under normal conditions) in situations of
severe inflammation or reduced liver and kidney function [18] or by genetic polymorphisms in
metabolism (UGT1A4) and transport (P-glycoprotein) or altered expression of these proteins.
The two cases emphasize detailed blood and urine steroid analyses (especially quan-
tification of aldosterone, tetrahydroaldosterone, cortisol, cortisone, their tetrahydro-
metabolites, 11-DOC, and 11-deoxycortisol) to unravel the underlying mechanism of the
posaconazole-induced hypertension and hypokalemia. Two distinct mechanisms (i.e., in-
hibition of 11b-hydroxylase and 11b-HSD2) were found to be responsible for posaconazole-
induced pseudohyperaldosteronism, with significant interindividual differences. Careful
consideration of comedications affecting the pharmacokinetics and pharmacodynamics is
warranted. In addition, further research on the impact of susceptibility factors such as
polymorphisms in genes encoding for proteins involved in metabolism or transport of pos-
aconazole is needed.
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